Dr. Tolaney on Key Findings From the ExteNET Trial in HER2+ Breast Cancer

Video

In Partnership With:

Sara M. Tolaney, MD, MPH, discusses data from the phase 3 ExteNET trial utilizing neratinib in the treatment of patients with HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, associate director, Susan F. Smith Center for Women's Cancers, director, Clinical Trials, Breast Oncology, director, Breast Immunotherapy Clinical Research, senior physician, Dana-Farber Cancer Institute; and associate professor of medicine, Harvard Medical School, discusses data from the phase 3 ExteNET trial (NCT00878709) utilizing neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

ExteNET enrolled patients with high-risk HER2-positive breast cancer. The trial examined the administration of 1 year of neratinib vs placebo in those who had completed a full year of trastuzumab (Herceptin). Results indicated that neratinib significantly improved invasive disease-free survival (iDFS) in this population, particularly in those with hormone receptor (HR)–positive disease, according to Tolaney.

Several subsequent exploratory analyses of the trial have demonstrated that when neratinib is initiated within 6 months of trastuzumab in this high-risk subset of patients who have HR-positive, HER2-positive disease, who did not achieve a prior pathologic complete response, it resulted in a significant iDFS and overall survival benefit.

These analyses also found numerically fewer brain metastases as a site for recurrence, making this study the first to show an impact on incidence of central nervous system metastases with adjuvant therapy, Tolaney concludes.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD